Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewVU 1545
Discontinued Product
3325 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
Description: Positive allosteric modulator of mGlu5 receptors
Chemical Name: N-[1-(2-Fluorophenyl)-3-phenyl-1H-pyrazol-5-yl]-4-nitrobenzamide
Purity: ≥98% (HPLC)
Biological Activity for VU 1545
VU 1545 is a metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (EC50 = 9.6 nM, Ki = 156 nM at rat mGlu5).
Technical Data for VU 1545
| M. Wt | 402.38 |
| Formula | C22H15FN4O3 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 890764-63-3 |
| PubChem ID | 11625520 |
| InChI Key | BRAZLURTFMCAHU-UHFFFAOYSA-N |
| Smiles | O=C(C4=CC=C([N+]([O-])=O)C=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2F |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for VU 1545
References for VU 1545
References are publications that support the biological activity of the product.
de Paulis et al (2006) Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J.Med.Chem. 49 3332 PMID: 16722652
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Modulators
Keywords: VU 1545, VU 1545 supplier, mGlu5, mGluR5, positive, allosteric, modulators, mGlur, Group, I, Receptors, Glutamate, Metabotropic, VU1545, PAM, (Metabotropic), 3325, Tocris Bioscience
Citations for VU 1545
Citations are publications that use Tocris products.
Currently there are no citations for VU 1545.
Reviews for VU 1545
There are currently no reviews for this product. Be the first to review VU 1545 and earn rewards!
Have you used VU 1545?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.